The Clinical Utility of the CA 19-9 Tumor-Associated Antigen

Steinberg, William
April 1990
American Journal of Gastroenterology;Apr1990, Vol. 85 Issue 4, p350
Academic Journal
Since Koprowski and coworkers discovered the CA 19-9 antigen 10 yr ago, it has become the most useful blood test in the diagnosis and management of patients with cancer of the pancreas. With an upper limit of normal of 37 U/ml, the assay's overall sensitivity is approximately 80% and its specificity is 90%. If higher cutoffs are used, the specificity rises so that, at levels greater than 1000 U/ml, the marker's specificity approaches 100%. Acute cholangitis and cirrhosis are two benign conditions that might raise this assay significantly. This tumor-associated marker is also helpful in predicting unresectability of pancreatic adenocarcinoma, as 96% of tumors that result in blood levels greater than 1000 U/ml have been found to be unresectable. After potentially curative surgery, the CA 19-9 can help prognosticate survival. Patients who normalize their CA 19-9 postoperatively live longer than those who do not. Furthermore, the assay, when used serially, predicts recurrence of disease prior to radiographic or clinical findings. The CA 19-9 is currently the "gold" standard marker for pancreatic cancer, against which other assays in this field will be judged.


Related Articles

  • Place de la radiothérapie dans la stratégie de traitement du carcinome hépatocellulaire. Girard, N.; Mornex, F.; Trepo, C.; Merle, P. // Oncologie;Jun2007, Vol. 9 Issue 6, p482 

    The optimal therapeutic strategy for hepatocellular carcinoma (HCC) in patients with cirrhosis remains elusive. Potentially curative treatments include liver transplantation, surgical resection and percutaneous ablation, but they are only feasible when HCC is limited in size. Conformal radiation...

  • Primary Hepatic Carcinoma. Sandlow, Leslie J.; Spellberg, Mitchell A. // American Journal of Gastroenterology;Dec1980, Vol. 74 Issue 6, p512 

    The records of all patients with primary hepatic carcinoma diagnosed between 1971 and 1976 at Michael Reese Hospital in Chicago were reviewed. Of 175,953 discharges only 43 were for primary hepatic carcinoma; one for 4,080 admissions as compared to one per 193 admissions for primary colonic...

  • Elastase Secretion in Pancreatic Disease. Mizuno, Ribun; Hayakawa, Tetsuo; Noda, Aiji // American Journal of Gastroenterology;Feb1985, Vol. 80 Issue 2, p113 

    To estimate the diagnostic value of elastase output in the duodenal aspirates during a pancreozymin secretin test, elastase as well as amylase, chymotrypsin, trypsin, and lipase was determined in 46 controls and 61 patients with various disease. The elastase output decreased significantly in...

  • Hepatocellular carcinoma in cirrhotic patients at multidetector CT: hepatic venous phase versus delayed phase for the detection of tumour washout. Furlan, A.; Marin, D.; Vanzulli, A.; Patera, G. Palermo; Ronzoni, A.; Midiri, M.; Bazzocchi, M.; Lagalla, R.; Brancatelli, G. // British Journal of Radiology;May2011, Vol. 84 Issue 1001, p403 

    Objectives: Our aim was to compare retrospectively hepatic venous and delayed phase images for the detection of tumour washout during multiphasic multidetector row CT (MDCT) of the liver in patients with hepatocellular carcinoma (HCC). Methods: 30 cirrhotic patients underwent multiphasic MDCT in...

  • Synchronous bilateral breast cancer in a male. Hernández, María Caridad Rubio; Prado, Yenia Ivet Díaz; Pérez, Suanly Rodríguez; Díaz, Ronald Rodríguez; Aleaga, Zaili Gutiérrez // Ecancermedicalscience;2013, Vol. 7 Issue 361-380, p1 

    Male breast cancer, which represents only 1% of all breast cancers, is occasionally associated with a family history of breast cancer. Sporadic male breast cancers presenting with another primary breast cancer are extremely rare. In this article, we report on a 70-year-old male patient with...

  • Debate: Resection for early hepatocellular carcinoma. Pawlik, Timothy M. // Journal of Gastrointestinal Surgery;Jun2009, Vol. 13 Issue 6, p1026 

    The management of patients with cirrhosis and early hepatocellular carcinoma (HCC) meeting the Milan criteria is controversial. Although liver transplantation for early HCC has been shown to have excellent long term survival rates and low recurrence rates, its application is limited by organ...

  • Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study. Hoyos, Sergio; Escobar, Jorge; Cardona, Doris; Guzmán, Carlos; Mena, Álvaro; Osorio, Germán; Pérez, Camilo; Restrepo, Juan C.; Correa, Gonzalo // Annals of Hepatology: Official Journal of the Mexican Associatio;Jan/Feb2015, Vol. 14 Issue 1, p58 

    Introduction. Hepatocellular carcinoma is the most common primary tumor of the liver and is diagnosed in more than a half million people worldwide each year. This study aims to assess factors associated with the recurrence and survival of patients with hepatocellular carcinoma and liver...

  • Coexistence of splenic marginal zone lymphoma with hepatocellular carcinoma: a case report. Shu-Hui Zhang; Ai-Min Xu; Jian-Ming Zheng; Miao-Xia He // Diagnostic Pathology;2007, Vol. 2, p5 

    Background: Coexistence of splenic marginal zone lymphoma with hepatocellular carcinoma is rare. Although some reports have suggested the possible pathogenic role of HBV, HCV, chronic and persistent antigenic stimulation in lymphoma, their role in causing lymphomas is still unclear. Case...

  • Hepatic Resection of Hepatocellular Carcinoma in Patients With Cirrhosis: Model of End-Stage Liver Disease (MELD) Score Predicts Perioperative Mortality Teh, Swee H.; Christein, John; Donohue, John; Que, Florencia; Kendrick, Michael; Farnell, Michael; Cha, Stephen; Kamath, Patrick; Kim, Raymond; Nagorney, David M. // Journal of Gastrointestinal Surgery;Dec2005, Vol. 9 Issue 9, p1207 

    Hepatic resection for hepatocellular carcinoma (HCC) in patients with cirrhosis is generally recommended for patients with Child-Turcotte-Pugh (CTP) Class A liver disease and early tumor stage. The Model for End-Stage Liver Disease (MELD) has been shown to accurately predict survival in patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics